BeOne Medicines Ltd.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: BeOne Medicines Ltd.
Ownership: Public
Status: Active
Headquarters country: Cayman Islands
Ticker symbol: ONC
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001651308

Board of directors

Follow this board

Alessandro Riva · Director
Since 2023
Anthony C. Hooper · Director
Since 2023
Charles Lazelle Sawyers · Director
Since 2026
Corazon (Corsee) D. Sanders · Director
Since 2023
Donald W. Glazer · Director
Since 2023
Elizabeth Fisher Mooney · Director
Since 2026
Felix Baker · Director Overboarded
Since 2023
John Oyler · Director · Chief Executive Officer
Since 2023
Julian Baker · Director Overboarded
Since 2023
Margaret Dugan · Director
Since 2023
Olivier Brandicourt · Director
Since 2024
Qingqing Yi · Director
Since 2023
Shalini Sharp · Director
Since 2024
Thomas Malley · Director
Since 2023
Xiaodong Wang · Director
Since 2023

Chief executives

John Oyler · Chief Executive Officer

Dates unknown

Board connections

8 of this board's directors also sit on 26 other boards.

Shared director Other board Same sector +10 more in the list below

Bicycle Therapeutics plc
via Alessandro Riva, Felix Baker and Julian Baker
Kiniksa Pharmaceuticals International plc
via Felix Baker, Julian Baker and Thomas Malley
ACADIA Pharmaceuticals Inc.
via Felix Baker and Julian Baker
DBV Technologies S.A.
via Felix Baker and Julian Baker
Denali Therapeutics Inc.
via Felix Baker and Julian Baker
Immunocore Holdings plc
via Felix Baker and Julian Baker
Incyte Corp.
via Felix Baker and Julian Baker
Kodiak Sciences Inc
via Felix Baker and Julian Baker
Kymera Therapeutics Inc.
via Felix Baker and Julian Baker
Madrigal Pharmaceuticals Inc.
via Felix Baker and Julian Baker
Neurogene Inc.
via Felix Baker and Julian Baker
Prelude Therapeutics Incorporated
via Felix Baker and Julian Baker
Replimune Group Inc.
via Felix Baker and Julian Baker
TScan Therapeutics Inc.
via Felix Baker and Julian Baker
vTv Therapeutics Inc.
via Felix Baker and Julian Baker
Alnylam Pharmaceuticals Inc.
via Olivier Brandicourt
Calidi Biotherapeutics Inc.
via Corazon (Corsee) D. Sanders
Century Therapeutics Inc.
via Alessandro Riva
Kura Oncology Inc.
via Thomas Malley
Legend Biotech Corporation
via Corazon (Corsee) D. Sanders
MannKind Corporation
via Anthony C. Hooper
Neurocrine Biosciences Inc.
via Shalini Sharp
Organon & Co.
via Shalini Sharp
Septerna Inc.
via Shalini Sharp
Ultragenyx Pharmaceutical Inc.
via Corazon (Corsee) D. Sanders
Vaxcyte Inc.
via Olivier Brandicourt

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $361,198,010; 192 sales by 12 insiders

Date	Insider	Transaction	Shares	Price	Value
Sep 8, 2026	Xiaodong Wang Director, Chair, Scientific Advisory Brd	Open-market sale	−1,181	$345.38	$407,897
Sep 8, 2026	Xiaodong Wang Director, Chair, Scientific Advisory Brd	Open-market sale	−2,841	$346.16	$983,433
Sep 8, 2026	Xiaodong Wang Director, Chair, Scientific Advisory Brd	Open-market sale	−1,517	$347.39	$526,993
Sep 8, 2026	Xiaodong Wang Director, Chair, Scientific Advisory Brd	Open-market sale	−1,721	$348.01	$598,930
Sep 8, 2026	Xiaodong Wang Director, Chair, Scientific Advisory Brd	Option exercise	+31,027	$36.90	$1,144,896
Sep 8, 2026	Xiaodong Wang Director, Chair, Scientific Advisory Brd	Open-market sale	−7,492	$348.31	$2,609,573
Sep 8, 2026	Xiaodong Wang Director, Chair, Scientific Advisory Brd	Open-market sale	−10,688	$349.28	$3,733,141
Sep 8, 2026	Xiaodong Wang Director, Chair, Scientific Advisory Brd	Open-market sale	−6,569	$350.27	$2,300,951
Sep 8, 2026	Xiaodong Wang Director, Chair, Scientific Advisory Brd	Open-market sale	−6,278	$351.25	$2,205,174
Sep 1, 2026	Ball Titus B. Officer (Principal Accounting Officer)	Open-market sale	−132	$355.86	$46,974
Aug 25, 2026	Wu Xiaobin Officer (President and COO)	Open-market sale	−280	$380.00	$106,400
Aug 12, 2026	John Oyler Director, Officer (Chief Executive Officer)	Open-market sale	−1,980	$354.71	$702,320
Aug 12, 2026	John Oyler Director, Officer (Chief Executive Officer)	Open-market sale	−2,515	$356.43	$896,426
Aug 12, 2026	John Oyler Director, Officer (Chief Executive Officer)	Open-market sale	−15,396	$357.63	$5,506,147
Aug 12, 2026	John Oyler Director, Officer (Chief Executive Officer)	Open-market sale	−20,899	$358.41	$7,490,448

Reviews (0)

No reviews yet. Be the first to write one.